Log in

MacroGenics Stock Forecast, Price & News

-0.58 (-2.84 %)
(As of 10/29/2020 12:00 AM ET)
Today's Range
Now: $19.87
50-Day Range
MA: $25.49
52-Week Range
Now: $19.87
Volume698,783 shs
Average Volume1.34 million shs
Market Capitalization$1.08 billion
P/E RatioN/A
Dividend YieldN/A
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; MGA012, an investigational monoclonal antibody targeting PD-1; MGD013, a monoclonal antibody that targets the PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing combination of MGD009 and MGA012; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD014, a DART molecule that targets envelope protein of human immunodeficiency virus infected cells and T cells. It has strategic collaborations with Incyte Corporation; Zai Lab Limited; and I-Mab Biopharma. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
Read More
MacroGenics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MGNX



Sales & Book Value

Annual Sales$64.19 million
Book Value$4.71 per share


Net Income$-151,810,000.00
Net Margins-214.06%


Market Cap$1.08 billion
Next Earnings Date11/4/2020 (Confirmed)
-0.58 (-2.84 %)
(As of 10/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

MacroGenics (NASDAQ:MGNX) Frequently Asked Questions

How has MacroGenics' stock been impacted by COVID-19 (Coronavirus)?

MacroGenics' stock was trading at $6.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MGNX shares have increased by 206.2% and is now trading at $19.87.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of MacroGenics?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 2 sell ratings, 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for MacroGenics

When is MacroGenics' next earnings date?

MacroGenics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for MacroGenics

How can I listen to MacroGenics' earnings call?

MacroGenics will be holding an earnings conference call on Wednesday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) released its quarterly earnings data on Thursday, July, 30th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.92) by $0.02. The biopharmaceutical company had revenue of $20.26 million for the quarter, compared to analyst estimates of $14.19 million. MacroGenics had a negative net margin of 214.06% and a negative return on equity of 72.15%.
View MacroGenics' earnings history

What price target have analysts set for MGNX?

14 Wall Street analysts have issued 1 year price targets for MacroGenics' shares. Their forecasts range from $8.00 to $50.00. On average, they expect MacroGenics' share price to reach $30.92 in the next twelve months. This suggests a possible upside of 55.6% from the stock's current price.
View analysts' price targets for MacroGenics

Are investors shorting MacroGenics?

MacroGenics saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 4,000,000 shares, an increase of 18.0% from the September 15th total of 3,390,000 shares. Based on an average trading volume of 500,500 shares, the short-interest ratio is presently 8.0 days.
View MacroGenics' Short Interest

Who are some of MacroGenics' key competitors?

What other stocks do shareholders of MacroGenics own?

Who are MacroGenics' key executives?

MacroGenics' management team includes the following people:
  • Dr. Scott Koenig, CEO, Pres & Director (Age 68, Pay $905.44k)
  • Mr. James Karrels, Sr. VP, CFO & Sec. (Age 53, Pay $533.25k)
  • Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 66, Pay $575.14k)
  • Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 47, Pay $531.38k)
  • Anna Krassowska Ph.D., VP of Investor Relations & Corp. Communications

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (1.17%), Candriam Luxembourg S.C.A. (1.08%), Pinnacle Associates Ltd. (0.79%), Sanders Morris Harris LLC (0.04%), DekaBank Deutsche Girozentrale (0.02%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own MacroGenics stock include Eric Blasius Risser, Ezio Bonvini, Jeffrey Stuart Peters, Kenneth Galbraith, Matthew K Fust and Thomas Spitznagel.
View institutional ownership trends for MacroGenics

Which institutional investors are selling MacroGenics stock?

MGNX stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., and Rhenman & Partners Asset Management AB. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, Ezio Bonvini, Kenneth Galbraith, and Thomas Spitznagel.
View insider buying and selling activity for MacroGenics

Which institutional investors are buying MacroGenics stock?

MGNX stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Sanders Morris Harris LLC, DekaBank Deutsche Girozentrale, Nisa Investment Advisors LLC, and Pacer Advisors Inc..
View insider buying and selling activity for MacroGenics

How do I buy shares of MacroGenics?

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $19.87.

How big of a company is MacroGenics?

MacroGenics has a market capitalization of $1.08 billion and generates $64.19 million in revenue each year. The biopharmaceutical company earns $-151,810,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. MacroGenics employs 384 workers across the globe.

What is MacroGenics' official website?

The official website for MacroGenics is www.macrogenics.com.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.

This page was last updated on 10/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.